Chinese Academy of

Oral supplementation of vitamin D (internal code VD50kIU2011) is a completed clinical program sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences investigating the use of vitamin D supplementation for obesity management. The program enrolled patients in a clinical trial (NCT01781169) that concluded by October 2013. The program evaluates vitamin D's potential metabolic and endocrine effects on weight management, though the specific mechanism of action in obesity remains not yet disclosed. The trial involved oral vitamin D administration, with ergocalciferol (vitamin D2) identified as a key investigational component. Ergocalciferol is an FDA-approved vitamin D receptor agonist with established regulatory status in the United States across multiple generic manufacturers. The program represents an early-stage exploration of micronutrient supplementation as an adjunctive obesity intervention, distinct from contemporary pharmacological weight-loss agents. Development status is completed, with the latest documented milestone occurring on 30 October 2013. No subsequent milestones, regulatory filings, or commercial development plans have been disclosed. The program does not appear to have progressed to formal regulatory submission or approval pathways.

Obesity remains a significant global public health challenge with limited pharmacological treatment options, particularly in 2011–2013 when this trial was conducted. Vitamin D deficiency has been epidemiologically associated with obesity and metabolic dysfunction in observational studies, creating a rationale for investigating supplementation as a potential intervention. The mechanistic hypothesis—that vitamin D repletion may improve metabolic parameters and support weight loss—addresses an unmet need for safe, accessible, and low-cost obesity treatments, especially in populations with concurrent vitamin D insufficiency. This approach differs fundamentally from contemporary obesity pharmacotherapy (GLP-1 receptor agonists, lipase inhibitors) by targeting a micronutrient deficiency rather than appetite or energy expenditure pathways. The competitive landscape for obesity treatment has evolved substantially since 2013, with newer agents demonstrating superior efficacy. However, vitamin D supplementation remains relevant for specific patient populations with documented deficiency and metabolic dysfunction. The program's completion without apparent regulatory advancement suggests either negative or inconclusive efficacy findings, or a strategic decision to deprioritize micronutrient-based obesity interventions in favor of pharmacological approaches. Market relevance is limited by the availability of over-the-counter vitamin D products and the lack of proprietary formulation or novel mechanism differentiation.

Drug Class: Vitamin D supplementation (micronutrient/dietary supplement)

Modality: Other (dietary supplement/micronutrient)

Active Ingredients: Ergocalciferol (vitamin D2) and vitamin (unspecified formulation)

Mechanism of Action: Ergocalciferol functions as a vitamin D receptor agonist, activating the vitamin D3 receptor to modulate calcium homeostasis, immune function, and metabolic pathways implicated in obesity and glucose metabolism.

Route of Administration: Oral

Target: Vitamin D3 receptor

Regulatory Status: Ergocalciferol is FDA-approved as a prescription and over-the-counter product with multiple generic manufacturers (ANDA040833, ANDA040865, and others). No novel formulation or indication-specific approval was sought or obtained for this obesity program.

Related Therapies: Vitamin D supplementation is available globally as a dietary supplement; prescription ergocalciferol is indicated for vitamin D deficiency and hypoparathyroidism, not obesity.

Patent Status: Not yet disclosed; ergocalciferol is off-patent.

United States (FDA): Ergocalciferol (vitamin D2) is approved as a prescription and over-the-counter product under multiple ANDA applications (ANDA040833, ANDA040865, ANDA080704, ANDA080747, ANDA080825, ANDA080884, ANDA080951, ANDA080956, ANDA083102, ANDA084053, ANDA090455, ANDA091004, ANDA204276) and NDA003444. Approved indications include vitamin D deficiency and hypoparathyroidism, not obesity. No FDA approval, IND, or NDA submission for obesity indication has been disclosed.

China (NMPA): Vitamin (unspecified) is listed as undergoing clinical trials in China (NCT01317849, NCT02407899, NCT02799134). The VD50kIU2011 program trial (NCT01781169) completed in 2013; regulatory status post-completion is not yet disclosed.

European Medicines Agency (EMA): Not yet disclosed.

Japan (PMDA): Not yet disclosed.

Program Status: The obesity indication for vitamin D supplementation has not advanced to regulatory filing or approval in any disclosed jurisdiction. The program is completed as a clinical trial; no label expansion, regulatory pathway, or commercial development has been announced.

Strategic Implications: The completion of this trial without apparent regulatory advancement or commercial development suggests either negative efficacy findings or a strategic deprioritization of micronutrient-based obesity interventions. Xiyuan Hospital's sponsorship indicates academic/institutional research rather than pharmaceutical industry development, limiting commercial viability and regulatory pathway resources.

Competitive Implications: By 2013, the obesity treatment landscape was beginning to shift toward pharmacological agents with superior efficacy (GLP-1 agonists, combination therapies). Vitamin D supplementation, lacking proprietary formulation or patent protection, could not compete on efficacy or differentiation. The absence of published trial results or regulatory filings suggests the program did not generate sufficient evidence to support obesity claims or justify commercial investment.

Future Catalysts: Publication of trial results in peer-reviewed literature remains the primary potential catalyst for scientific impact, though regulatory or commercial development appears unlikely. No expected next milestone has been disclosed.

Expected Milestones: None disclosed. The program appears dormant post-2013 completion.

Evidence-Based Assessment: The program represents an early-stage, hypothesis-driven exploration of micronutrient supplementation for obesity—a mechanism distinct from contemporary pharmacotherapy. The lack of regulatory advancement, published results, or commercial development over the past decade indicates the program did not generate sufficient clinical or commercial momentum to progress.